JP2021119164A5 - - Google Patents

Download PDF

Info

Publication number
JP2021119164A5
JP2021119164A5 JP2021074407A JP2021074407A JP2021119164A5 JP 2021119164 A5 JP2021119164 A5 JP 2021119164A5 JP 2021074407 A JP2021074407 A JP 2021074407A JP 2021074407 A JP2021074407 A JP 2021074407A JP 2021119164 A5 JP2021119164 A5 JP 2021119164A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
buffer solution
compound
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021074407A
Other languages
English (en)
Japanese (ja)
Other versions
JP7223053B2 (ja
JP2021119164A (ja
Filing date
Publication date
Priority claimed from JP2017566743A external-priority patent/JP6876631B2/ja
Application filed filed Critical
Publication of JP2021119164A publication Critical patent/JP2021119164A/ja
Publication of JP2021119164A5 publication Critical patent/JP2021119164A5/ja
Application granted granted Critical
Publication of JP7223053B2 publication Critical patent/JP7223053B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021074407A 2015-06-23 2021-04-26 白金化合物、組成物及びその使用 Active JP7223053B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562183403P 2015-06-23 2015-06-23
US62/183,403 2015-06-23
US201562268666P 2015-12-17 2015-12-17
US62/268,666 2015-12-17
JP2017566743A JP6876631B2 (ja) 2015-06-23 2016-06-22 白金化合物、組成物及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017566743A Division JP6876631B2 (ja) 2015-06-23 2016-06-22 白金化合物、組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2021119164A JP2021119164A (ja) 2021-08-12
JP2021119164A5 true JP2021119164A5 (enExample) 2021-09-24
JP7223053B2 JP7223053B2 (ja) 2023-02-15

Family

ID=57586683

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017566743A Expired - Fee Related JP6876631B2 (ja) 2015-06-23 2016-06-22 白金化合物、組成物及びその使用
JP2021074407A Active JP7223053B2 (ja) 2015-06-23 2021-04-26 白金化合物、組成物及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017566743A Expired - Fee Related JP6876631B2 (ja) 2015-06-23 2016-06-22 白金化合物、組成物及びその使用

Country Status (4)

Country Link
US (2) US10342801B2 (enExample)
EP (1) EP3313392B1 (enExample)
JP (2) JP6876631B2 (enExample)
WO (1) WO2016209918A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056897T2 (hu) 2015-12-09 2022-03-28 Univ Wien Med Monomaleimid-funkcionalizált platinavegyületek rákterápiához
CA3062369A1 (en) 2017-05-05 2018-11-08 Intezyne Technologies, Inc. Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008001101A2 (en) * 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
US9090640B2 (en) * 2011-09-02 2015-07-28 Ulrich Bierbach Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
WO2014100417A1 (en) * 2012-12-19 2014-06-26 Blend Therapeutics, Inc. Compounds, compositions, and methods for the treatment of cancers
WO2015102922A1 (en) * 2013-12-31 2015-07-09 Blend Therapeutics, Inc. Compounds, compositions, and methods for the treatment of cancers
EP3797768A1 (en) * 2014-06-23 2021-03-31 Placon Therapeutics, Inc. Maleimide-functionalised platinum for use in the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2020007356A5 (enExample)
RU2012108632A (ru) Сублингвальные и буккальные пленочные композиции
JP2018021007A5 (enExample)
JP2019504086A5 (enExample)
JP2021119164A5 (enExample)
FI3817751T3 (fi) Vedettömän natriumtiosulfaatin formulaatioita
JP2009521473A5 (enExample)
RU2006118689A (ru) Содержащий фармацевтический агент состав с покрытием
ES2897981T3 (es) Composición de dos componentes que comprende ácido acetilsalicílico
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
JP2020510619A5 (enExample)
WO2018226987A1 (en) Compositions for treating fungal and bacterial biofilms and methods of using the same
JPWO2018221487A1 (ja) エリブリンまたはその薬剤学的に許容される塩を含む注射剤
ES2946237T3 (es) Sistemas de dos componentes que comprenden ácido acetilsalicílico y una sal de carbonato
JPH0692849A (ja) フラン誘導体を含有する医薬組成物
CA2466770A1 (en) Liquid pharmaceutical formulations of acetaminophen and an alkali metal 1-lactate salt
JP2019502751A5 (enExample)
CA2514124A1 (en) Absorption enhancing agents
JP7525701B2 (ja) カルボプラチンの非経口剤形
CN1636553A (zh) 防挥发型固体制剂及其制造方法
CN1210028C (zh) 水性液体制剂
US20180064711A1 (en) Methods for treating cryptosporidiosis using triazolopyridazines
RU2011134414A (ru) Комбинация фульвовой кислоты для лечения различных состояний и болезней
JP2007534731A5 (enExample)
RU2812137C2 (ru) Способ стабилизации влагочувствительного фармацевтического вещества и его стабилизированный препарат